Revance Therapeutics (NASDAQ: RVNC) announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance expects to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE